Antifibrotic therapies in the liver

Seminars in Liver Disease

Volumn 35, Issue 2, 2015, Pages 184-198

  Mehal, Wajahat Z ^a,b   Schuppan, D ^c,d  

^a YALE UNIVERSITY   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cirrhosis; collagen; fibroblast; fibrosis; liver; macrophage; myofibroblast; progression; regression; stellate cells; therapy

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTIFIBROTIC AGENT; BOSENTAN; CANDESARTAN; DOCOSAHEXAENOIC ACID; ELAFIBRANOR; ENTECAVIR; ETANERCEPT; FARGLITAZAR; FG 3019; ICOSAPENTAENOIC ACID; IMATINIB; IRBESARTAN; LIRAGLUTIDE; LOSARTAN; METFORMIN; NINTEDANIB; NIVOCASAN; OBETICHOLIC ACID; OLTIPRAZ; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PIRFENIDONE; ROSIGLITAZONE; SALVIANOLIC ACID B; SIMTUZUMAB; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; ANGIOGENESIS INHIBITOR;

ARTICLE; BARIATRIC SURGERY; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE DELETION; GENETIC MODEL; HUMAN; IMMUNE RESPONSE; LIVER FIBROSIS; MOLECULAR PATHOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; STELLATE CELL; BIOLOGICAL THERAPY; DISEASE COURSE; LIVER CIRRHOSIS; PROCEDURES;

ANGIOGENESIS INHIBITORS; CELL- AND TISSUE-BASED THERAPY; DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS;

EID: 84929321561     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0035-1550055     Document Type: Article

References (146)

1. Schuppan D., Kim Y. O. Evolving therapies for liver fibrosis. J Clin Invest: 2013; 123 5 1887 1901
2. Mederacke I., Hsu C. C., Troeger J. S., et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun: 2013; 4 2823
3. Wells R. G. Portal fibroblasts in biliary fibrosis. Curr Pathobiol Rep: 2014; 2 4 185 190
4. Luedde T., Kaplowitz N., Schwabe R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology: 2014; 147 4 765 783.e4
5. Friedman S. L., Sheppard D., Duffield J. S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med: 2013; 5 167 167sr1
6. Marcellin P., Cooper C., Balart L., et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology: 2013; 145 4 790 800.e3
7. Popov Y., Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology: 2009; 50 4 1294 1306
8. Pockros P. J., Jeffers L., Afdhal N., et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology: 2007; 45 3 569 578
9. McHutchison J., Goodman Z., Patel K., et al. Farglitizar Study Investigators. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology: 2010; 138 4 1365 1373, 1373.e1-1373.e2
10. Grompe M., Strom S. Mice with human livers. Gastroenterology: 2013; 145 6 1209 1214
11. Popov Y., Sverdlov D. Y., Sharma A. K., et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology: 2011; 140 5 1642 1652
12. Yoshida S., Ikenaga N., Liu S. B., et al. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice. Gastroenterology: 2014; 147 6 1378 1392
13. Takahashi Y., Soejima Y., Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol: 2012; 18 19 2300 2308
14. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nature reviews. Gastroenterol Hepatol: 2011; 8 35 44
15. Charlton M., Krishnan A., Viker K., et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol: 2011; 301 5 G825 G834
16. Ueberham E., Löw R., Ueberham U., Schönig K., Bujard H., Gebhardt R. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology: 2003; 37 5 1067 1078
17. Czochra P., Klopcic B., Meyer E., et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol: 2006; 45 3 419 428
18. Campbell J. S., Hughes S. D., Gilbertson D. G., et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A: 2005; 102 9 3389 3394
19. Seki E., Schwabe R. F. Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology: 2015; 61 3 1066 1079
20. Olinga P., Schuppan D. Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol: 2013; 58 6 1252 1253
21. de Graaf I. A., Olinga P., de Jager M. H., et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc: 2010; 5 9 1540 1551
22. Mestas J., Hughes C. C. Of mice and not men: differences between mouse and human immunology. J Immunol: 2004; 172 5 2731 2738
23. Mehal W. Z., Iredale J., Friedman S. L. Scraping fibrosis: expressway to the core of fibrosis. Nat Med: 2011; 17 5 552 553
24. Pellicoro A., Ramachandran P., Iredale J. P., Fallowfield J. A. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol: 2014; 14 3 181 194
25. Kubes P., Mehal W. Z. Sterile inflammation in the liver. Gastroenterology: 2012; 143 5 1158 1172
26. Yona S., Kim K. W., Wolf Y., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity: 2013; 38 1 79 91
27. Tacke F., Zimmermann H. W. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol: 2014; 60 5 1090 1096
28. Karlmark K. R., Weiskirchen R., Zimmermann H. W., et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology: 2009; 50 1 261 274
29. Hayashidani S., Tsutsui H., Shiomi T., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation: 2003; 108 17 2134 2140
30. Lucas T., Waisman A., Ranjan R., et al. Differential roles of macrophages in diverse phases of skin repair. J Immunol: 2010; 184 7 3964 3977
31. Lin S. L., Castaño A. P., Nowlin B. T., Lupher M. L. Jr, Duffield J. S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol: 2009; 183 10 6733 6743
32. Ramachandran P., Pellicoro A., Vernon M. A., et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A: 2012; 109 46 E3186 E3195
33. Pradere J. P., Kluwe J., De Minicis S., et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology: 2013; 58 4 1461 1473
34. Wynn T. A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis: 2010; 30 3 245 257
35. Thompson J. E., Vaughan T. J., Williams A. J., et al. A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy. J Immunol Methods: 1999; 227 1-2 17 29
36. Mori Y., Ishida W., Bhattacharyya S., Li Y., Platanias L. C., Varga J. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum: 2004; 50 12 4008 4021
37. Ueno H., Sakamoto T., Nakamura T., et al. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther: 2000; 11 1 33 42
38. Yata Y., Gotwals P., Koteliansky V., Rockey D. C. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology: 2002; 35 5 1022 1030
39. Vogt J., Traynor R., Sapkota G. P. The specificities of small molecule inhibitors of the TGFβ and BMP pathways. Cell Signal: 2011; 23 11 1831 1842
40. Gilliam B. L., Riedel D. J., Redfield R. R. Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med: 2011; 9 01 S9
41. Zaldivar M. M., Pauels K., von Hundelshausen P., et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology: 2010; 51 4 1345 1353
42. Hawinkels L. J., Ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors: 2011; 29 4 140 152
43. Duffield J. S., Forbes S. J., Constandinou C. M., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest: 2005; 115 1 56 65
44. Pellicoro A., Aucott R. L., Ramachandran P., et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology: 2012; 55 6 1965 1975
45. Popov Y., Sverdlov D. Y., Bhaskar K. R., et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol: 2010; 298 3 G323 G334
46. Wynn T. A., Cheever A. W., Jankovic D., et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature: 1995; 376 6541 594 596
47. Shi Z., Wakil A. E., Rockey D. C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A: 1997; 94 20 10663 10668
48. Chiaramonte M. G., Donaldson D. D., Cheever A. W., Wynn T. A. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest: 1999; 104 6 777 785
49. May C., Sapra P., Gerber H. P. Advances in bispecific biotherapeutics for the treatment of cancer. Biochem Pharmacol: 2012; 84 9 1105 1112
50. Wan J., Benkdane M., Teixeira-Clerc F., et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology: 2014; 59 1 130 142
51. Barron L., Wynn T. A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol: 2011; 300 5 G723 G728
52. Duffield J. S., Lupher M., Thannickal V. J., Wynn T. A. Host responses in tissue repair and fibrosis. Annu Rev Pathol: 2013; 8 241 276
53. Muhanna N., Abu Tair L., Doron S., et al. Amelioration of hepatic fibrosis by NK cell activation. Gut: 2011; 60 1 90 98
54. Radaeva S., Sun R., Jaruga B., Nguyen V. T., Tian Z., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology: 2006; 130 2 435 452
55. Gao B., Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta: 2013; 1832 7 1061 1069
56. McHedlidze T., Waldner M., Zopf S., et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity: 2013; 39 2 357 371
57. Iwakiri Y., Shah V., Rockey D. C. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol: 2014; 61 4 912 924
58. Bhunchet E., Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology: 1993; 18 6 1450 1458
59. Herbst H., Frey A., Heinrichs O., et al. Heterogeneity of liver cells expressing procollagen types I and IV in vivo. Histochem Cell Biol: 1997; 107 5 399 409
60. Shah V., Haddad F. G., Garcia-Cardena G., et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest: 1997; 100 11 2923 2930
61. Langer D. A., Das A., Semela D., et al. Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology: 2008; 47 6 1983 1993
62. Deleve L. D., Wang X., Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology: 2008; 48 3 920 930
63. Tugues S., Fernandez-Varo G., Muñoz-Luque J., et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology: 2007; 46 6 1919 1926
64. Thabut D., Routray C., Lomberk G., et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology: 2011; 54 2 573 585
65. Yang L., Kwon J., Popov Y., et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology: 2014; 146 5 1339 50.e1
66. Ding B. S., Cao Z., Lis R., et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature: 2014; 505 7481 97 102
67. Marra F., Tacke F. Roles for chemokines in liver disease. Gastroenterology: 2014; 147 3 577 594.e1
68. Kinnman N., Francoz C., Barbu V., et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest: 2003; 83 2 163 173
69. Nocito A., Georgiev P., Dahm F., et al. Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology: 2007; 45 2 369 376
70. Schuppan D., Cramer T., Bauer M., Strefeld T., Hahn E. G., Herbst H. Hepatocytes as a source of collagen type XVIII endostatin. Lancet: 1998; 352 9131 879 880
71. Schuppan D., Ruehl M., Somasundaram R., Hahn E. G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis: 2001; 21 3 351 372
72. Myers J. C., Li D., Bageris A., Abraham V., Dion A. S., Amenta P. S. Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. Am J Pathol: 1997; 151 6 1729 1740
73. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis: 1990; 10 1 1 10
74. Arthur M. J., Iredale J. P., Mann D. A. Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease. Alcohol Clin Exp Res: 1999; 23 5 940 943
75. Iredale J. P., Thompson A., Henderson N. C. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta: 2013; 1832 7 876 883
76. Janmey P. A., Wells R. G., Assoian R. K., McCulloch C. A. From tissue mechanics to transcription factors. Differentiation: 2013; 86 3 112 120
77. Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev: 2005; 24 3 395 402
78. Aluwihare P., Mu Z., Zhao Z., et al. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J Cell Sci: 2009; 122 Pt 2 227 232
79. Henderson N. C., Sheppard D. Integrin-mediated regulation of TGFβ in fibrosis. Biochim Biophys Acta: 2013; 1832 7 891 896
80. Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell: 2002; 110 6 673 687
81. Huttenlocher A., Horwitz A. R. Integrins in cell migration. Cold Spring Harb Perspect Biol: 2011; 3 9 a005074
82. Campbell I. D., Humphries M. J. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol: 2011; 3 3 4994
83. Munger J. S., Huang X., Kawakatsu H., et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell: 1999; 96 3 319 328
84. Mu D., Cambier S., Fjellbirkeland L., et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol: 2002; 157 3 493 507
85. Wipff P. J., Rifkin D. B., Meister J. J., Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol: 2007; 179 6 1311 1323
86. Patsenker E., Popov Y., Stickel F., Jonczyk A., Goodman S. L., Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology: 2008; 135 2 660 670
87. Kitamura H., Cambier S., Somanath S., et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β J Clin Invest: 2011; 121 7 2863 2875
88. Popov Y., Patsenker E., Stickel F., et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol: 2008; 48 3 453 464
89. Wang B., Dolinski B. M., Kikuchi N., et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology: 2007; 46 5 1404 1412
90. Shull M. M., Ormsby I., Kier A. B., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature: 1992; 359 6397 693 699
91. Henderson N. C., Arnold T. D., Katamura Y., et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med: 2013; 19 12 1617 1624
92. Zhou X., Murphy F. R., Gehdu N., Zhang J., Iredale J. P., Benyon R. C. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem: 2004; 279 23 23996 24006
93. Patsenker E., Popov Y., Stickel F., et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology: 2009; 50 5 1501 1511
94. Issa R., Zhou X., Constandinou C. M., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology: 2004; 126 7 1795 1808
95. Lucero H. A., Kagan H. M. Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci: 2006; 63 19-20 2304 2316
96. Kagan H. M., Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem: 2003; 88 4 660 672
97. Barker H. E., Cox T. R., Erler J. T. The rationale for targeting the LOX family in cancer. Nat Rev Cancer: 2012; 12 8 540 552
98. Kagan H. M. Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis. Pathol Res Pract: 1994; 190 9-10 910 919
99. Barry-Hamilton V., Spangler R., Marshall D., et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med: 2010; 16 9 1009 1017
100. Vadasz Z., Kessler O., Akiri G., et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol: 2005; 43 3 499 507
101. Perepelyuk M., Terajima M., Wang A. Y., et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol: 2013; 304 6 G605 G614
102. Kisseleva T., Cong M., Paik Y., et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A: 2012; 109 24 9448 9453
103. Troeger J. S., Mederacke I., Gwak G. Y., et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology: 2012; 143 4 1073 83.e22
104. Olsen A. L., Bloomer S. A., Chan E. P., et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol: 2011; 301 1 G110 G118
105. Wynn T. A., Ramalingam T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med: 2012; 18 7 1028 1040
106. Baeck C., Wei X., Bartneck M., et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology: 2014; 59 3 1060 1072
107. Samarakoon R., Overstreet J. M., Higgins P. J. TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal: 2013; 25 1 264 268
108. Wang Q., Usinger W., Nichols B., et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair: 2011; 4 1 4
109. Muñoz-Luque J., Ros J., Fernández-Varo G., et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther: 2008; 324 2 475 483
110. Tam J., Cinar R., Liu J., et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab: 2012; 16 2 167 179
111. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature: 2012; 482 7384 179 185
112. Mehal W. Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol: 2013; 10 11 637 644
113. Bohinc B. N., Diehl A. M. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis: 2012; 16 3 549 565
114. Mudaliar S., Henry R. R., Sanyal A. J., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology: 2013; 145 3 574 82.e1
115. Guy C. D., Suzuki A., Zdanowicz M., et al. NASH CRN. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology: 2012; 55 6 1711 1721
116. Wood N. J. Microbiota: dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression. Nat Rev Gastroenterol Hepatol: 2012; 9 3 123
117. Phung N., Pera N., Farrell G., Leclercq I., Hou J. Y., George J. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med: 2009; 24 2 171 180
118. Paik Y. H., Iwaisako K., Seki E., et al. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology: 2011; 53 5 1730 1741
119. Jiang J. X., Venugopal S., Serizawa N., et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology: 2010; 139 4 1375 1384
120. Jiang J. X., Chen X., Serizawa N., et al. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med: 2012; 53 2 289 296
121. Thannickal V. J. Mechanisms of pulmonary fibrosis: role of activated myofibroblasts and NADPH oxidase. Fibrogenesis Tissue Repair: 2012; 5 (Suppl 1 Proceedings of Fibroproliferative disorders: from biochemical analysis to targeted therapies Petro E Petrides and David Brenner) S23
122. Aoyama T., Paik Y. H., Watanabe S., et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology: 2012; 56 6 2316 2327
123. Torok N. J., Dranoff J. A., Schuppan D., et al. Strategies and endpoints of antifibrotic drug trials. Summary and Recommendations from the AASLD Emerging Trends Conference 2014. Hepatology 2015, in press
124. Vilar Gomez E., Gra Oramas B., Soler E., Llanio Navarro R., Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int: 2007; 27 2 247 259
125. Liu P., Hu Y. Y., Liu C., et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol: 2002; 8 4 679 685
126. Liu P., Hu Y. Y., Liu C., et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol: 2005; 11 19 2892 2899
127. Poupon R. E., Poupon R., Balkau B.; The UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med: 1994; 330 19 1342 1347
128. Corpechot C., Carrat F., Bonnand A. M., Poupon R. E., Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology: 2000; 32 6 1196 1199
129. Kim M. Y., Cho M. Y., Baik S. K., et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. Liver Int: 2012; 32 6 977 987
130. Belfort R., Harrison S. A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med: 2006; 355 22 2297 2307
131. Aithal G. P., Thomas J. A., Kaye P. V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology: 2008; 135 4 1176 1184
132. Sanyal A. J., Chalasani N., Kowdley K. V., et al. NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med: 2010; 362 18 1675 1685
133. Ratziu V., Charlotte F., Bernhardt C., et al. LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology: 2010; 51 2 445 453
134. Zein C. O., Yerian L. M., Gogate P., et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology: 2011; 54 5 1610 1619
135. Torres D. M., Jones F. J., Shaw J. C., Williams C. D., Ward J. A., Harrison S. A. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial. Hepatology: 2011; 54 5 1631 1639
136. Ratziu V., de Ledinghen V., Oberti F., et al. FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol: 2011; 54 5 1011 1019
137. Neuschwander-Tetri B. A., Loomba R., Sanyal A. J., et al. for the NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet: 2014; 14 61934
138. Chavez-Tapia N. C., Tellez-Avila F. I., Barrientos-Gutierrez T., Mendez-Sanchez N., Lizardi-Cervera J., Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev: 2010; 1 1 CD007340
139. Raghu G., Brown K. K., Costabel U., et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med: 2008; 178 9 948 955
140. Demedts M., Behr J., Buhl R., et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med: 2005; 353 21 2229 2242
141. Daniels C. E., Lasky J. A., Limper A. H., Mieras K., Gabor E., Schroeder D. R.; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med: 2010; 181 6 604 610
142. Raghu G., Behr J., Brown K. K., et al. ARTEMIS-IPF Investigators∗. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med: 2013; 158 9 641 649
143. Noble P. W., Albera C., Bradford W. Z., et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet: 2011; 377 9779 1760 1769
144. Taniguchi H., Ebina M., Kondoh Y., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Resp J: 2010; 35 4 821 829
145. King T. E. Jr, Bradford W. Z., Castro-Bernardini S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med: 2014; 370 2083 2092
146. Richeldi L., du Bois R. M., Raghu G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med: 2014; 370 2071 2082